FLATEXDEGIRO-AG
28.8.2024 09:52:28 CEST | Business Wire | Press release
Oliver Behrens appointed as new Chief Executive Officer (CEO)
flatexDEGIRO AG (the “Company”), one of the leading and fastest growing online brokers in Europe, announces that the Company’s Supervisory Board has appointed Oliver Behrens (60) as Chief Executive Officer (CEO) of flatexDEGIRO AG, effective from October 1, 2024, for a duration of three years. Furthermore, Oliver Behrens will also take over as CEO of flatexDEGIRO Bank AG.
Oliver Behrens brings 40 years of experience in the European financial industry with a strong link to brokerage and an outstanding network in international finance and politics.
From 2015 to June 2024, Oliver Behrens lately was CEO of Morgan Stanley Europe Holding SE, Morgan Stanley Europe SE and Morgan Stanley Bank AG, Frankfurt am Main, as well as Member of the Board of Morgan Stanley International Limited, London. Moreover, until 2014, he also served as Member of the Board of Deka-Bank for nine years, lately as Deputy CEO. From 1992 to 2005, he worked in Frankfurt and Luxembourg, among others, across various functions in the former DWS Group, DWS and Deutsche Asset Management, where he was lately Spokesman of the Management Board of Deutsche Asset Management Investment GmbH. Since June 2024, Oliver Behrens is Chairman of DWS Group GmbH & Co. KGaA’s Supervisory Board.
Oliver Behrens takes over from Dr Benon Janos (52) and Stephan Simmang (58), who, since May 1, 2024, serve as interim Co-CEOs of the Company, in addition to their existing responsibilities as CFO and CTO, respectively.
On his appointment as new CEO of flatexDEGIRO AG, Oliver Behrens commented: "The European online brokerage business is still in its early innings, holding enormous potential for growth and value enhancement. Together with flatexDEGIRO’s strong leadership team, I am very much looking forward to leading the company into the next phase of its evolution, further enhancing the investment experience for millions of clients across 16 countries while firmly establishing flatexDEGIRO as the driving force in the European online brokerage market.”
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “With Oliver Behrens, we have succeeded in engaging a real heavyweight of the European financial industry for this leading role at flatexDEGIRO. It fills us with pride and speaks for the great potential of flatexDEGIRO that we have been able to recruit an executive of his caliber for the vacant CEO position. With his outstanding industry experience and his strong, team-orientated leadership personality, Oliver Behrens is a real gain, both operationally and organizationally, for our company which he already knows very well from the long-standing and cooperative business relationships with his previous employer.”
The appointment of Oliver Behrens as CEO of flatexDEGIRO AG and flatexDEGIRO Bank AG is subject to customary approvals by the German Federal Financial Supervisory Authority (BaFin).
Appointment of Dr Benon Janos (CFO) as Deputy CEO
Moreover, the Company’s Supervisory Board has appointed Dr Benon Janos (CFO) as Deputy CEO of flatexDEGIRO AG, effective from October 1, 2024. Dr Benon Janos will also fulfil this function at flatexDEGIRO Bank AG.
Contract extension of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until mid-2029
Furthermore, the Supervisory Board of flatexDEGIRO has also decided to extend the Management Board contracts of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until May 31, 2029. Dr Benon Janos and Stephan Simmang have held management positions at flatexDEGIRO since 2016, serving as members of the Company’s Management Board since 2023.
Therefore, effective from October 1, 2024, flatexDEGIRO AG’s Management Board will consist of four members, namely Oliver Behrens (CEO), Dr Benon Janos (Deputy CEO & CFO), Stephan Simmang (CTO) and Christiane Strubel (CHRO).
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “On behalf of the whole Supervisory Board, I would like to express our deepest gratitude to Dr Benon Janos and Stephan Simmang for stepping up and taking on additional responsibilities as Co-CEOs during the past months, ensuring a professional and orderly transition after the departure of the former CEO. The Supervisory Board is very much looking forward to extending the great collaboration over the coming years and expressly thanks Dr Benon Janos and Stephan Simmang for their leadership and integrity, especially during this critical transition phase.”
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge, high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering for clients and set leading standards in terms of product, price and platform quality.
With around 3 million customer accounts and around 60 million securities transactions processed in 2023, flatexDEGIRO is one of the largest retail online brokers in Europe. In times of bank consolidation, low real interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth.
Further information can be found at https://www.flatexdegiro.com/en.
| Language: | English | |
| Company: | flatexDEGIRO AG | |
| Omniturm, Große Gallusstraße 16-18 | ||
| 60312 Frankfurt / Main | ||
| Germany | ||
| Phone: | +49 (0) 69 450001 0 | |
| E-mail: | ir@flatexdegiro.com | |
| Internet: | www.flatexdegiro.com | |
| ISIN: | DE000FTG1111 | |
| WKN: | FTG111 | |
| Indices: | SDAX | |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828514871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom